Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Helix BioPharma Corp

HBP.TO ✓ COMPLIANTFree checks used up today ☆ Track — members

TSE · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$1.00

▲ +0.00%

Market Cap $76.44M · Vol 452

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$76.44M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

27.68

Momentum

Beta

-0.29

vs Market

52W High

$3.86

74.16% below

52W Low

$0.79

28.36% above

Volume

452

Avg 2.91K

P/B

5.09

Price-to-book

ROE

N/A

Return on equity

Free Float

58.10%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Helix BioPharma Corp (HBP.TO) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does HBP.TO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-7.89%

-30.69%

-6.04%

-23.91%

YTD

-40.93%

-6.67%

+8.28%

-63.64%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-3,757,580.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-51.30% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.09
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	76.38M

Technical Indicators

50-Day SMA	$1.17
200-Day SMA	$1.31
RSI (14)	27.68
Beta	-0.29
52-Week High	$3.86
52-Week Low	$0.79

Volume Today	452
Avg Daily Volume (30D)	2.91K
Relative Volume	0.16x
Volatility (10D)	61.92
Volatility (30D)	76.08
Free Float	58.10%

Analyst Consensus

N/A

Current Price $1.00

Mean Target N/A

52W Low$0.79 52W High$3.86

Current

Target

$0.79 $3.86

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSE

FIGIBBG001S66SP8

ISINCA4229102088

CountryCanada

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The Company is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.